Key Events This Week
25 May: Intraday high of ₹714.95 with a 7.62% surge
25 May: Quality grade upgraded to "Good"
25 May: Upgraded to Hold rating by MarketsMOJO
26 May: Technical momentum shifts to sideways trend
29 May: Intraday high of ₹725 with 7.64% gain
29 May: Hits upper circuit limit, closing at ₹742.15 (+10.0%)

Sudeep Pharma Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent
2026-05-29 15:00:14At Rs 742.15, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sudeep Pharma Ltd locked at its upper circuit of 10% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
Sudeep Pharma Ltd Surges 7.64% to Day's High of Rs 725 — Outperforms Sector by 5.72 Percentage Points
2026-05-29 10:18:54The Sensex advanced 0.24% on 29 May 2026, yet Sudeep Pharma Ltd outpaced the broader market with a robust 7.64% gain, reaching an intraday high of Rs 725. This 5.72 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.
Read full news article
Sudeep Pharma Ltd Technical Momentum Shifts Amid Sideways Trend
2026-05-26 08:07:51Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a robust 3.77% gain on 26 May 2026, the stock’s technical indicators suggest a nuanced outlook, with mixed signals from MACD, RSI, and moving averages. This article analyses the recent price action, technical parameters, and relative performance against the Sensex to provide a comprehensive view for investors.
Read full news article
Sudeep Pharma Ltd Surges 7.62% to Day's High of Rs 714.95 — Outperforms Sector by 5.79 Percentage Points
2026-05-25 11:01:15The Sensex advanced 1.21% on 25 May 2026, yet Sudeep Pharma Ltd outpaced the broader market with a 7.62% gain, reaching an intraday high of Rs 714.95. This 5.79-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.
Read full news article









